These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39201536)

  • 1. Differential Expression of PACAP/VIP Receptors in the Post-Mortem CNS White Matter of Multiple Sclerosis Donors.
    Jansen MI; Musumeci G; Castorina A
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Alterations of PACAP and VIP Expression in the Female Rat Brain Following Spinal Cord Injury.
    Broome ST; Mandwie M; Gorrie CA; Musumeci G; Marzagalli R; Castorina A
    J Mol Neurosci; 2023 Oct; 73(9-10):724-737. PubMed ID: 37646964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.
    Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V
    Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
    Moody TW; Nuche-Berenguer B; Jensen RT
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):38-47. PubMed ID: 26702849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAC1 receptors mediate pituitary adenylate cyclase-activating polypeptide- and progesterone-facilitated receptivity in female rats.
    Apostolakis EM; Riherd DN; O'Malley BW
    Mol Endocrinol; 2005 Nov; 19(11):2798-811. PubMed ID: 15976009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
    J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC
    Tasma Z; Rees TA; Guo S; Tan S; O'Carroll SJ; Faull RLM; Curtis MA; Christensen SL; Hay DL; Walker CS
    Br J Pharmacol; 2024 Aug; 181(15):2655-2675. PubMed ID: 38616050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotective role of the VIP signaling system.
    Dvoráková MC
    Timely Top Med Cardiovasc Dis; 2005 Oct; 9():E33. PubMed ID: 16341283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VIP and PACAP effects on mouse major pelvic ganglia neurons.
    Tompkins JD; Girard BM; Vizzard MA; Parsons RL
    J Mol Neurosci; 2010 Nov; 42(3):390-6. PubMed ID: 20428965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
    Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
    J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors.
    Langer I; Latek D
    Front Endocrinol (Lausanne); 2021; 12():711906. PubMed ID: 34867774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PACAP/VIP and receptor characterization in micturition pathways in mice with overexpression of NGF in urothelium.
    Girard BM; Malley SE; Braas KM; May V; Vizzard MA
    J Mol Neurosci; 2010 Nov; 42(3):378-89. PubMed ID: 20449688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
    Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells.
    de Boisvilliers M; Perrin F; Hebache S; Balandre AC; Bensalma S; Garnier A; Vaudry D; Fournier A; Festy F; Muller JM; Chadéneau C
    Peptides; 2016 Apr; 78():30-41. PubMed ID: 26826611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.
    Ramos-Álvarez I; Mantey SA; Nakamura T; Nuche-Berenguer B; Moreno P; Moody TW; Maderdrut JL; Coy DH; Jensen RT
    Peptides; 2015 Apr; 66():26-42. PubMed ID: 25698233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
    Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.